Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Juvederm

- PMLiVE

Merck buys cough drug developer Afferent for $1.25bn

Gains access to pipeline with potential for development in ‘neurogenic’ indications

- PMLiVE

Trial of AbbVie’s Rova-T disappoints at ASCO

But company says the modest trial data is “a good early sign” for lung cancer drug

AstraZeneca AZ

AZ sells Zurampic rights to Gruenenthal for $230m

Continues to sell off unwanted assets in order to focus resources and meet $45bn sales target

Bayer symbol

Bayer confirms bid for Monsanto; will pharma suffer?

Analysts fear agrochemical $62bn deal will hinder its medicines business

Novartis building

Novartis splits pharma unit as Epstein exits

Restructure sees creation of standalone cancer arm Novartis Oncology

Allergan logo

Allergan on course to file uterine fibroid drug next year

New drug could be safer and more effective than existing treatment

- PMLiVE

Pfizer split still on cards – for tax reasons

Firm continues to look for ways to reduce tax burden

Allergan logo

Allergan eyes early 2017 European launch for Enzepi

CHMP backs the enzyme replacement therapy's approval

- PMLiVE

AbbVie boosts immuno-oncology pipeline with $685m Argenx deal

Buys rights to immuno-suppressive antibody and will fund further research

- PMLiVE

US tax changes claim Pfizer scalp as Allergan deal abandoned

Firm walks away from record-breaking $160bn merger after planned inversion rule changes released

- PMLiVE

Gilead boosts liver disease pipeline with $1.2bn acquisition

Also has combination HIV therapy Descovy approved by FDA

- PMLiVE

Pfizer and Allergan: The challenge starts now

The Pfizer and Allergan merger is a game changer in the pharmaceutical industry, creating the biggest drug maker in the world. The complexities of reaching this landmark agreement cannot be...

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links